Esperion Therapeutics (ESPR) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a sell rating to a hold rating in a research note published on Friday morning.

Other equities analysts have also issued reports about the company. Northland Securities reissued a buy rating and set a $72.00 price target on shares of Esperion Therapeutics in a research note on Friday, November 10th. UBS Group set a $88.00 price target on Esperion Therapeutics and gave the company a buy rating in a research note on Wednesday, January 17th. Stifel Nicolaus set a $105.00 price target on Esperion Therapeutics and gave the company a buy rating in a research note on Monday, January 15th. Bank of America raised Esperion Therapeutics from a neutral rating to a buy rating and set a $76.00 price target for the company in a research note on Friday, January 5th. Finally, BidaskClub raised Esperion Therapeutics from a hold rating to a buy rating in a research note on Saturday, December 16th. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Esperion Therapeutics has a consensus rating of Buy and a consensus target price of $77.23.

Esperion Therapeutics (NASDAQ ESPR) opened at $65.94 on Friday. The firm has a market capitalization of $1,690.00, a PE ratio of -9.61 and a beta of 2.64. Esperion Therapeutics has a one year low of $13.41 and a one year high of $82.18.

In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total transaction of $502,205.10. Following the sale, the director now directly owns 2,472 shares in the company, valued at $133,117.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 32.50% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Chartwell Investment Partners LLC purchased a new stake in Esperion Therapeutics during the third quarter valued at approximately $1,374,000. Meditor Group Ltd raised its position in Esperion Therapeutics by 305.5% during the third quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock valued at $115,022,000 after purchasing an additional 1,728,935 shares during the period. Macquarie Group Ltd. purchased a new stake in Esperion Therapeutics during the second quarter valued at approximately $1,182,000. Hamilton Lane Advisors LLC purchased a new stake in Esperion Therapeutics during the fourth quarter valued at approximately $7,594,000. Finally, OxFORD Asset Management LLP purchased a new stake in Esperion Therapeutics during the third quarter valued at approximately $715,000. Institutional investors and hedge funds own 92.85% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/02/06/esperion-therapeutics-espr-stock-rating-upgraded-by-valuengine.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit